カテゴリー： 世界, 医療/バイオ, Allied Market Research

結核治療薬の世界市場2021-2031：機会分析・産業予測

【英語タイトル】Tuberculosis Treatment Drugs Market By Disease Type (Active Tuberculosis, Latent Tuberculosis), By Therapy Type (First Line Therapy, Second Line Therapy), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Allied Market Researchが出版した調査資料（ALD23JUN080）・商品コード：ALD23JUN080
・発行会社（調査会社）：Allied Market Research
・発行日：2023年3月
・ページ数：322
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

アライドマーケットリサーチ社の市場調査レポートでは、世界の結核治療薬市場規模が、2021年の1,929.96百万ドルから2031年には3,243.90百万ドルまで拡大し、2022年から2031年までの予測期間中、年平均成長率は5.3％を記録すると推測されています。当レポートでは、結核治療薬の世界市場について多面的に調査・分析を行い、イントロダクション、エグゼクティブサマリー、市場概要、疾患種類別（活動性結核、潜在性結核）分析、治療種類別（第一選択治療、第二選択治療）分析、流通チャネル別（病院薬局、ドラッグストア・小売薬局、オンラインプロバイダー）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）分析、競争状況、企業情報などの内容を整理しています。なお、記載されている企業情報には、Lupin、Sanofi、Pfizer Inc.、FRESENIUS SE & Co. KGaA (Fresenius Kabi)、Johnson & Johnson、Novartis AG、Macleods Pharmaceuticals Ltd.、ANI Pharmaceuticals, Inc.、Otsuka Pharmaceutical Co., Ltd.、Teva Pharmaceutical Industries Ltd.などが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の結核治療薬市場規模：疾患種類別
- 活動性結核における市場規模
- 潜在性結核における市場規模
・世界の結核治療薬市場規模：治療種類別
- 第一選択治療における市場規模
- 第二選択治療における市場規模
・世界の結核治療薬市場規模：流通チャネル別
- 病院薬局チャネルの市場規模
- ドラッグストア・小売薬局チャネルの市場規模
- オンラインプロバイダーチャネルの市場規模
・世界の結核治療薬市場規模：地域別
- 北米の結核治療薬市場規模
- ヨーロッパの結核治療薬市場規模
- アジア太平洋の結核治療薬市場規模
- 中南米/中東・アフリカの結核治療薬市場規模
・競争状況
・企業情報

結核治療薬市場は2021年に19億2,996万ドルと評価され、2031年には32億4,390万ドルに達すると予測されます。2022年から2031年までの年平均成長率は5.3%となる見込みです。

結核は、結核菌によって引き起こされる感染症です。結核は主に肺に感染しますが、腎臓、骨、脳など他の部位にも感染することがあります。結核は、感染者が咳をしたり、くしゃみをしたり、話したりすることで空気感染します。結核は空気感染する病気であり、感染した飛沫を吸い込むことで人から人へと容易に感染します。結核の診断は通常、病歴、身体診察、胸部X線検査、喀痰顕微鏡検査や培養検査などの臨床検査の組み合わせに基づいて行われます。さらに、イソニアジド、リファンピン、エタンブトールなどの第一選択薬や、シクロステリン、エチオアミド、カプレオマイシンなどの第二選択薬が認可され、結核治療に使用されています。
結核治療薬市場を牽引する要因は、結核患者の増加です。例えば、米国疾病予防管理センター（CDC）の2022年の報告によると、2021年には結核患者が78億8,200万人、すなわち9.4%増加したと記載されています。このように、結核患者の増加は、市場の成長を促進すると予想される薬剤に対する高い需要をもたらします。さらに、今後数年間で規制当局の承認を受けると予想される結核治療薬のパイプラインの増加が、予測期間中の成長を促進するでしょう。

さらに、さまざまなプログラムやキャンペーンを通じて、結核疾患や利用可能な治療法に関する患者の認識を高めるための非政府組織や政府組織によるイニシアチブの増加は、市場の成長を後押しすると予測されます。加えて、結核を診断するための先端技術の採用と早期診断の重要性に関する認識の高まりが、市場の成長を押し上げると予測されます。さらに、多くの主要企業が、世界の結核治療薬市場における存在感を高めるために、提携、合意、アライアンスなどの主要戦略を採用しており、これが市場の成長を促進すると予想されます。

しかし、結核治療薬に関連する主な副作用などの要因は、結核治療薬市場の成長を抑制する可能性があります。また、広範な薬剤耐性の増加が市場の成長を妨げる可能性があります。
さらに、結核治療のための新規治療薬に対する需要の増加や、新規治療薬に対する規制承認の増加とともにパイプライン分子の強力な存在は、市場の主要プレーヤーに有利な機会を提供すると期待されています。

世界の結核治療薬市場は、疾患タイプ、治療タイプ、流通チャネル、地域に区分されます。
疾患タイプ別では、活動性結核と潜在性結核に分類されます。
治療タイプ別では、ファーストライン治療とセカンドライン治療に分類されます。
流通チャネル別では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダーに分類されます。
地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州）、アジア太平洋（日本、中国、インド、その他アジア太平洋）、LAMEA（中南米、中東、アフリカ）に区分して分析しています。

世界の結核治療薬市場で事業を展開する主な主要企業は、Lupin、Sanofi、Pfizer Inc.、Fresenius SE & Co. KGaA (Fresenius Kabi)、Johnson & Johnson、Teva Pharmaceuticals、Novartis AG、ANI Pharmaceuticals Inc.、大塚製薬株式会社、Macleods Pharmaceuticals Ltd.などです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの結核治療薬市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、優勢な結核治療薬市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・結核治療薬市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域および世界の結核治療薬市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
疾患タイプ別
活動性結核
潜在性結核

治療タイプ別
ファーストライン治療
セカンドライン治療

販売チャネル別
病院薬局
ドラッグストア＆小売薬局
オンラインプロバイダー

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
インド
その他のアジア太平洋地域
・LAMEA
ラテンアメリカ
中東・アフリカ

〈主要市場プレイヤー〉
Lupin
Sanofi
Pfizer Inc.
FRESENIUS SE & Co. KGaA (Fresenius Kabi)
Johnson & Johnson
Novartis AG
Macleods Pharmaceuticals Ltd.
ANI Pharmaceuticals, Inc.
大塚製薬株式会社
Teva Pharmaceutical Industries Ltd.

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in R&D for tuberculosis drugs
3.4.1.2. Growing initiatives from government organizations for tuberculosis awareness
3.4.1.3. Rise in adoption of combinational therapy

3.4.2. Restraints
3.4.2.1. Adverse effects of Anti-Tuberculosis Drugs
3.4.2.2. Stringent Regulatory Guidelines for product approval

3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Active Tuberculosis
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Latent Tuberculosis
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. First Line Therapy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Second Line Therapy
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug Stores and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: TUBERCULOSIS TREATMENT DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Disease Type
7.2.3. Market size and forecast, by Therapy Type
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Disease Type
7.2.5.1.3. Market size and forecast, by Therapy Type
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Disease Type
7.2.5.2.3. Market size and forecast, by Therapy Type
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Disease Type
7.2.5.3.3. Market size and forecast, by Therapy Type
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Disease Type
7.3.3. Market size and forecast, by Therapy Type
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Disease Type
7.3.5.1.3. Market size and forecast, by Therapy Type
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Disease Type
7.3.5.2.3. Market size and forecast, by Therapy Type
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Disease Type
7.3.5.3.3. Market size and forecast, by Therapy Type
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Disease Type
7.3.5.4.3. Market size and forecast, by Therapy Type
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Disease Type
7.3.5.5.3. Market size and forecast, by Therapy Type
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Disease Type
7.3.5.6.3. Market size and forecast, by Therapy Type
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Disease Type
7.4.3. Market size and forecast, by Therapy Type
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Disease Type
7.4.5.1.3. Market size and forecast, by Therapy Type
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Disease Type
7.4.5.2.3. Market size and forecast, by Therapy Type
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Disease Type
7.4.5.3.3. Market size and forecast, by Therapy Type
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. Rest of Asia-Pacific
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Disease Type
7.4.5.4.3. Market size and forecast, by Therapy Type
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Disease Type
7.5.3. Market size and forecast, by Therapy Type
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Latin America
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Disease Type
7.5.5.1.3. Market size and forecast, by Therapy Type
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Middle East And Africa
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Disease Type
7.5.5.2.3. Market size and forecast, by Therapy Type
7.5.5.2.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. Lupin
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Macleods Pharmaceuticals Ltd.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.3. Sanofi
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Otsuka Pharmaceutical Co., Ltd.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Key strategic moves and developments
9.5. Pfizer Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. FRESENIUS SE & Co. KGaA (Fresenius Kabi)
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Johnson & Johnson
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Teva Pharmaceutical Industries Ltd.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Novartis AG
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. ANI Pharmaceuticals, Inc.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments

LIST OF TABLES
TABLE 01. GLOBAL TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 02. TUBERCULOSIS TREATMENT DRUGS MARKET FOR ACTIVE TUBERCULOSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 03. TUBERCULOSIS TREATMENT DRUGS MARKET FOR LATENT TUBERCULOSIS, BY REGION, 2021-2031 ($MILLION)
TABLE 04. GLOBAL TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 05. TUBERCULOSIS TREATMENT DRUGS MARKET FOR FIRST LINE THERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 06. TUBERCULOSIS TREATMENT DRUGS MARKET FOR SECOND LINE THERAPY, BY REGION, 2021-2031 ($MILLION)
TABLE 07. GLOBAL TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 08. TUBERCULOSIS TREATMENT DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 09. TUBERCULOSIS TREATMENT DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
TABLE 10. TUBERCULOSIS TREATMENT DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
TABLE 11. TUBERCULOSIS TREATMENT DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 12. NORTH AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 13. NORTH AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 14. NORTH AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 15. NORTH AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 16. U.S. TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 17. U.S. TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 18. U.S. TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 19. CANADA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 20. CANADA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 21. CANADA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 22. MEXICO TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 23. MEXICO TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 24. MEXICO TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 25. EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 26. EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 27. EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 28. EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 29. GERMANY TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 30. GERMANY TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 31. GERMANY TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 32. FRANCE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 33. FRANCE TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 34. FRANCE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 35. UK TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 36. UK TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 37. UK TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 38. ITALY TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 39. ITALY TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 40. ITALY TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 41. SPAIN TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 42. SPAIN TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 43. SPAIN TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 44. REST OF EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 45. REST OF EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 46. REST OF EUROPE TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 47. ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 48. ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 49. ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 50. ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 51. JAPAN TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 52. JAPAN TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 53. JAPAN TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 54. CHINA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 55. CHINA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 56. CHINA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 57. INDIA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 58. INDIA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 59. INDIA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 60. REST OF ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 61. REST OF ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 62. REST OF ASIA-PACIFIC TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 63. LAMEA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 64. LAMEA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 65. LAMEA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 66. LAMEA TUBERCULOSIS TREATMENT DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 67. LATIN AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 68. LATIN AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 69. LATIN AMERICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 70. MIDDLE EAST AND AFRICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISEASE TYPE, 2021-2031 ($MILLION)
TABLE 71. MIDDLE EAST AND AFRICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY THERAPY TYPE, 2021-2031 ($MILLION)
TABLE 72. MIDDLE EAST AND AFRICA TUBERCULOSIS TREATMENT DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
TABLE 73. LUPIN: KEY EXECUTIVES
TABLE 74. LUPIN: COMPANY SNAPSHOT
TABLE 75. LUPIN: PRODUCT SEGMENTS
TABLE 76. LUPIN: PRODUCT PORTFOLIO
TABLE 77. LUPIN: KEY STRATERGIES
TABLE 78. MACLEODS PHARMACEUTICALS LTD.: KEY EXECUTIVES
TABLE 79. MACLEODS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
TABLE 80. MACLEODS PHARMACEUTICALS LTD.: PRODUCT SEGMENTS
TABLE 81. MACLEODS PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
TABLE 82. SANOFI: KEY EXECUTIVES
TABLE 83. SANOFI: COMPANY SNAPSHOT
TABLE 84. SANOFI: PRODUCT SEGMENTS
TABLE 85. SANOFI: PRODUCT PORTFOLIO
TABLE 86. OTSUKA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
TABLE 87. OTSUKA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 88. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT SEGMENTS
TABLE 89. OTSUKA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 90. OTSUKA PHARMACEUTICAL CO., LTD.: KEY STRATERGIES
TABLE 91. PFIZER INC.: KEY EXECUTIVES
TABLE 92. PFIZER INC.: COMPANY SNAPSHOT
TABLE 93. PFIZER INC.: PRODUCT SEGMENTS
TABLE 94. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 95. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): KEY EXECUTIVES
TABLE 96. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): COMPANY SNAPSHOT
TABLE 97. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT SEGMENTS
TABLE 98. FRESENIUS SE & CO. KGAA (FRESENIUS KABI): PRODUCT PORTFOLIO
TABLE 99. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 100. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 101. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 102. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 103. JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 106. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 107. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 108. NOVARTIS AG: KEY EXECUTIVES
TABLE 109. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 110. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 111. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 112. ANI PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 113. ANI PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 114. ANI PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 115. ANI PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 116. ANI PHARMACEUTICALS, INC.: KEY STRATERGIES

★調査レポート[結核治療薬の世界市場2021-2031：機会分析・産業予測] (コード：ALD23JUN080)販売に関する免責事項を必ずご確認ください。
★調査レポート[結核治療薬の世界市場2021-2031：機会分析・産業予測]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 注射ペンの世界市場2021-2031：機会分析・産業予測
  • 多発性骨髄腫の世界市場2021-2031：機会分析・産業予測
  • 温熱療法の世界市場2021-2031：機会分析・産業予測
  • 神経変性治療薬の世界市場2021-2031：機会分析・産業予測
  • リハビリテーション装置の世界市場2021-2031：機会分析・産業予測
  • アテローム切除術機器の世界市場2021-2031：機会分析・産業予測
  • 尿分析検査の世界市場2021-2031：機会分析・産業予測
  • 脳マッピング機器の世界市場2021-2031：機会分析・産業予測
  • 個別化医療の世界市場2021-2031：機会分析・産業予測
  • 皮膚消毒剤の世界市場2021-2031：機会分析・産業予測

    • ◆H&Iグローバルリサーチのお客様（例）◆